Tags

Type your tag names separated by a space and hit enter

Radioimmunoassay in diagnosis, localization and treatment of endocrine tumours in gut and pancreas.
Scand J Gastroenterol Suppl. 1979; 53:33-8.SJ

Abstract

Pancreas and gut hormones are involved in many endocrine and gastrointestinal diseases. Radioimmunoassays for these hormones have proved particularly valuable in diagnosis, localisation and control of treatment of endocrine tumours, of which many are mixed. An estimate based on ten years experience in a homogenous population of 5 million inhabitants (Denmark) suggests, that endocrine gut tumour-syndromes on an average appear with an incidence of 1 patient per year/syndrome/million. At present six different syndromes are known: 1) The insulinoma syndrome, 2) The Zollinger-Ellison syndrome.3) The Verner-Morrison syndrome. 4) The glucagonoma syndrome. 5) The somatostatinoma syndrome, and 6) the carcinoid syndrome. Accordingly diagnostically valuable RIAs for pancreas and gut hormones include those for insulin, gastrin, VIP, HPP, glucagon, somatostatin, and presumably also substance P. It is probably safe to predict that the need for gut and pancreas hormone RIAs within the next decade will increase greatly in order to assure proper management of tumours producing gastroentero-pancreatic hormones.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

225784

Citation

Rehfeld, J F.. "Radioimmunoassay in Diagnosis, Localization and Treatment of Endocrine Tumours in Gut and Pancreas." Scandinavian Journal of Gastroenterology. Supplement, vol. 53, 1979, pp. 33-8.
Rehfeld JF. Radioimmunoassay in diagnosis, localization and treatment of endocrine tumours in gut and pancreas. Scand J Gastroenterol Suppl. 1979;53:33-8.
Rehfeld, J. F. (1979). Radioimmunoassay in diagnosis, localization and treatment of endocrine tumours in gut and pancreas. Scandinavian Journal of Gastroenterology. Supplement, 53, 33-8.
Rehfeld JF. Radioimmunoassay in Diagnosis, Localization and Treatment of Endocrine Tumours in Gut and Pancreas. Scand J Gastroenterol Suppl. 1979;53:33-8. PubMed PMID: 225784.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Radioimmunoassay in diagnosis, localization and treatment of endocrine tumours in gut and pancreas. A1 - Rehfeld,J F, PY - 1979/1/1/pubmed PY - 1979/1/1/medline PY - 1979/1/1/entrez SP - 33 EP - 8 JF - Scandinavian journal of gastroenterology. Supplement JO - Scand J Gastroenterol Suppl VL - 53 N2 - Pancreas and gut hormones are involved in many endocrine and gastrointestinal diseases. Radioimmunoassays for these hormones have proved particularly valuable in diagnosis, localisation and control of treatment of endocrine tumours, of which many are mixed. An estimate based on ten years experience in a homogenous population of 5 million inhabitants (Denmark) suggests, that endocrine gut tumour-syndromes on an average appear with an incidence of 1 patient per year/syndrome/million. At present six different syndromes are known: 1) The insulinoma syndrome, 2) The Zollinger-Ellison syndrome.3) The Verner-Morrison syndrome. 4) The glucagonoma syndrome. 5) The somatostatinoma syndrome, and 6) the carcinoid syndrome. Accordingly diagnostically valuable RIAs for pancreas and gut hormones include those for insulin, gastrin, VIP, HPP, glucagon, somatostatin, and presumably also substance P. It is probably safe to predict that the need for gut and pancreas hormone RIAs within the next decade will increase greatly in order to assure proper management of tumours producing gastroentero-pancreatic hormones. SN - 0085-5928 UR - https://www.unboundmedicine.com/medline/citation/225784/Radioimmunoassay_in_diagnosis_localization_and_treatment_of_endocrine_tumours_in_gut_and_pancreas_ L2 - https://medlineplus.gov/pancreaticcancer.html DB - PRIME DP - Unbound Medicine ER -